Skip to search formSkip to main content

GSK2251052

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
In Vitro and In Vivo Activities of DS86760016, a Novel Leucyl-tRNA Synthetase Inhibitor for Gram-Negative Pathogens.
The emergence of multidrug-resistant (MDR) Gram-negative bacilli is a major concern in the treatment of nosocomial infections… Expand
Is this relevant?
2016
2016
A Polymorphism in leuS Confers Reduced Susceptibility to GSK2251052 in a Clinical Isolate of Staphylococcus aureus.
GSK2251052 is a broad-spectrum antibacterial inhibitor of leucyl tRNA-synthetase (LeuRS) that has been evaluated in phase II… Expand
Is this relevant?
2015
2015
Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections.
GSK2251052, a novel leucyl-tRNA synthetase (LeuRS) inhibitor, was in development for the treatment of infections caused by… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2013
2013
Intrapulmonary pharmacokinetics of GSK2251052 in healthy volunteers.
The plasma and intrapulmonary pharmacokinetics (PK) of intravenous (i.v.) GSK2251052, a novel boron-containing antimicrobial… Expand
Is this relevant?
2013
2013
Determination of disk diffusion and MIC quality control guidelines for GSK2251052: a novel boron-containing antibacterial.
GSK2251052 is a boron-containing antimicrobial agent in clinical development for the treatment of serious Gram-negative bacterial… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
2013
2013
Disposition and metabolism of GSK2251052 in humans: a novel boron-containing antibiotic.
(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (GSK2251052) is a novel boron-containing… Expand
Is this relevant?
2013
2013
Comparative in vitro activities of GSK2251052, a novel boron-containing leucyl-tRNA synthetase inhibitor, against 916 anaerobic organisms.
We studied the comparative in vitro activity of GSK2251052, a novel boron leucyl-tRNA synthetase inhibitor, against 916 clinical… Expand
Is this relevant?
2013
2013
Disposition and Metabolism of GSK 2251052 in Humans : A Novel Boron-Containing Antibiotic s
(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro2,1-benzoxaborole (GSK2251052) is a novel boron-containing… Expand
  • figure 2
  • table 1
  • figure 3
  • table 2
  • figure 4
Is this relevant?
2013
2013
Intrapulmonary pharmacokinetics of GSK 2251052 in Healthy Volunteers
10 Running Title: Pulmonary and Plasma PK of GSK2251052 11 12 13 # Corresponding author: Parul Patel, Pharm.D. 14 GlaxoSmithKline… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
2011
2011
GSK2251052, a Novel Boron-containing Protein Synthesis Inhibitor, with Comparative in vitro Activity against Pseudomonas aeruginosa from a Global Population
Background: GSK2251052 (formerly AN3365), a novel boron-containing leucyl-tRNA synthetase inhibitor with in vitro activity… Expand
Is this relevant?